Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy.
Pegylated interferon-alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon-alpha therapy.
Gheorghe
Liana
L
Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. drgheorghe@gmail.com
Cotruta
Bogdan
B
Trifu
Viorel
V
Cotruta
Cristina
C
Becheanu
Gabriel
G
Gheorghe
Cristian
C
D000284:Administration, Oral; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D011241:Prednisone